Sequana Medical NV (SEQUA.BR)

1.4200 +0.0300 (+2.16%) At close: 05:35PM CEST

Sequana Medical NV

Kortrijksesteenweg 1112
box 102 Sint-Denijs-Westrem
Ghent 9051
Belgium
32 9 298 28 28
https://www.sequanamedical.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 62

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ian Crosbie	CEO & Executive Director	440.57k	N/A	N/A
Ms. Kirsten Van Bockstaele	Chief Financial Officer	355.98k	N/A	1975
Ms. Lies Vanneste	Director of Investor Relations	N/A	N/A	N/A
Mr. Martijn Blom	Chief Commercial Officer	N/A	N/A	1974
Dr. Oliver Godje M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1965

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Ghent, Belgium.

Corporate governance

Sequana Medical NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.